Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
AstraZeneca
Mallinckrodt
Baxter
Colorcon
Johnson and Johnson

Last Updated: November 22, 2019

DrugPatentWatch Database Preview

DEPO-SUBQ PROVERA 104 Drug Profile

See Plans and Pricing

« Back to Dashboard

When do Depo-subq Provera 104 patents expire, and what generic alternatives are available?

Depo-subq Provera 104 is a drug marketed by Pharmacia And Upjohn and is included in one NDA. There is one patent protecting this drug.

This drug has forty-three patent family members in twenty-nine countries.

The generic ingredient in DEPO-SUBQ PROVERA 104 is medroxyprogesterone acetate. There are twenty drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the medroxyprogesterone acetate profile page.

Summary for DEPO-SUBQ PROVERA 104
International Patents:43
US Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 68
Clinical Trials: 51
Patent Applications: 4,460
Formulation / Manufacturing:see details
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for DEPO-SUBQ PROVERA 104
DailyMed Link:DEPO-SUBQ PROVERA 104 at DailyMed
Drug patent expirations by year for DEPO-SUBQ PROVERA 104
Recent Clinical Trials for DEPO-SUBQ PROVERA 104

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
MU-JHU CAREPhase 4
University of California, San DiegoEarly Phase 1
Nationwide Children's HospitalPhase 4

See all DEPO-SUBQ PROVERA 104 clinical trials

Recent Litigation for DEPO-SUBQ PROVERA 104

Identify potential future generic entrants

District Court Litigation
Case NameDate
EAGLE PHARMACEUTICALS, INC. v. ACCORD HEALTHCARE, INC.2019-03-27

See all DEPO-SUBQ PROVERA 104 litigation

Pharmacology for DEPO-SUBQ PROVERA 104
Drug ClassProgestin
Synonyms for DEPO-SUBQ PROVERA 104
(6-alpha)-17-(Acetyloxy)-6-methylpreg-4-ene-3,20-dione
(6-alpha)-Pregn-4-ene-3,20-dione, 17-(acetyloxy)-6-methyl-
(6?)-6-Methyl-3,20-dioxopregn-4-en-17-yl acetate
(6.alpha.-Pregn-4-ene-3, 17-(acetyloxy)-6-methyl-
(6alpha)-17-(Acetyloxy)-6-methylpreg-4-ene-3,20-dione
(6alpha)-6-methyl-3,20-dioxopregn-4-en-17-yl acetate
(6S,8R,9S,10R,13S,14S,17R)-17-Acetyl-6,10,13-trimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl acetate
[(6S,8R,9S,10R,13S,14S,17R)-17-acetyl-6,10,13-trimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate
010M483
16534-EP2269990A1
16534-EP2272517A1
16534-EP2275102A1
16534-EP2275413A1
16534-EP2281563A1
16534-EP2281815A1
16534-EP2287156A1
16534-EP2289893A1
16534-EP2289894A2
16534-EP2295550A2
16534-EP2298731A1
16534-EP2298743A1
16534-EP2298768A1
16534-EP2301933A1
16534-EP2305640A2
16534-EP2308861A1
16534-EP2311807A1
16534-EP2311827A1
16534-EP2314574A1
16534-EP2316459A1
17-Acetoxy-6-alpha-methylprogesterone
17-Acetoxy-6.alpha.-methylprogesterone
17-Acetoxy-6alpha-methylprogesterone
17-alpha-Acetoxy-6-alpha-methylpregn-4-ene-3,20-dione
17-alpha-Hydroxy-6-alpha-methylpregn-4-ene-3,20-dione acetate
17-alpha-Hydroxy-6-alpha-methylprogesterone acetate
17-Hydroxy-6alpha-methylpregn-4-ene-3,20-dione acetate
17.alpha.-Acetoxy-6-.alpha.-methylpregn-4-ene-3,20-dione
17.alpha.-Acetoxy-6.alpha.-methylprogesterone
17.alpha.-Hydroxy-6-.alpha.-methylprogesterone acetate
17.alpha.-Hydroxy-6.alpha.-methylpregn-4-ene-3,20-dione acetate
17.alpha.-Hydroxy-6.alpha.-methylprogesterone acetate
17alpha-Acetoxy-6-alpha-methylpregn-4-ene-3,20-dione
17alpha-Acetoxy-6alpha-methylprogesterone
17alpha-Hydroxy-6-alpha-methylprogesterone acetate
17alpha-Hydroxy-6alpha-methylpregn-4-ene-3,20-dione acetate
17alpha-Hydroxy-6alpha-methylprogesterone acetate
4-08-00-02212 (Beilstein Handbook Reference)
6-alpha-Methyl-17-acetoxy progesterone
6-alpha-Methyl-17-alpha-acetoxypregn-4-ene-3,20-dione
6-alpha-Methyl-17-alpha-acetoxyprogesterone
6-alpha-Methyl-17-alpha-hydroxyprogesterone acetate
6-alpha-Methyl-17alpha-hydroxyprogesterone Acetate
6-alpha-Methyl-4-pregnene-3,20-dion-17-alpha-ol acetate
6.alpha.-Methyl-17-acetoxyprogesterone
6.alpha.-Methyl-17.alpha.-acetoxypregn-4-ene-3,20-dione
6.alpha.-Methyl-17.alpha.-acetoxyprogesterone
6.alpha.-Methyl-17.alpha.-hydroxyprogesterone acetate
6.alpha.-Methyl-4-pregnene-3,20-dion-17.alpha.-ol acetate
6.alpha.-Pregn-4-ene-3, 17-(acetyloxy)-6-methyl-
6alpha-Methyl-17-acetoxy progesterone
6alpha-Methyl-17-acetoxyprogesterone
6alpha-Methyl-17alpha-acetoxypregn-4-ene-3,20-dione
6alpha-Methyl-17alpha-hydroxyprogesterone acetate
6alpha-Methyl-4-pregnene-3,20-dion-17alpha-ol acetate
6alpha-Pregn-4-ene-3,20-dione, 17-(acetyloxy)-6-methyl-
71-58-9
92480-EP2295416A2
92480-EP2295426A1
92480-EP2295427A1
92480-EP2298748A2
92480-EP2298768A1
92480-EP2305642A2
AB00384270_15
AB00384270-14
AB2000663
AC-2174
AC1L1M6L
AI3-60127
AKOS015894870
Amen
AN-14229
Aragest
Aragest 5
AS-13981
BDBM50067678
BRN 2066112
C-21458
C08150
C2QI4IOI2G
CAS-71-58-9
CC-30186
CCRIS 371
CHEBI:6716
CHEMBL717
Clinofem
Clinovir
CM0089
CPD000653524
CS-2583
Cykrina
D00951
DB00603
Depcorlutin
Depo-clinovir
Depo-Map
Depo-Medroxyprogesterone acetate
Depo-Prodasone
Depo-progestin
Depo-Progevera
Depo-Promone
Depo-Provera
Depo-provera (TN)
Depo-Provera Contraceptive
Depo-ProveraContraceptive
Depo-Ralovera
Depo-subq provera
Depo-subq provera 104 (TN)
Depocon
Depomedroxyprogesterone acetate
Deporone
Depot medroxyprogesterone acetate
Depot-medroxyprogesterone acetate
DP150
DSSTox_CID_5527
DSSTox_GSID_25527
DSSTox_RID_77819
DTXSID0025527
Dugen
EINECS 200-757-9
Farlutin
Gestapuran
HMS2233O07
HMS2235E05
HMS3259O14
HY-B0469
Hysron
I028
Indivina
KS-00001F8G
LS-1607
Lutopolar
Lutoral
MAP (steroid)
Med-Pro
Medrosterona
Medroxiprogesterone Acetate
Medroxyacetate progesterone
Medroxyprogesterone (acetate)
Medroxyprogesterone 17-acetate
Medroxyprogesterone 17-acetate, >=97% (HPLC)
Medroxyprogesterone 17-acetate, VETRANAL(TM), analytical standard
Medroxyprogesterone 17-acetate;MPA
Medroxyprogesterone acetate
Medroxyprogesterone acetate (JP17/USP)
Medroxyprogesterone acetate [JAN]
Medroxyprogesterone acetate [Progestins]
Medroxyprogesterone acetate [USP:JAN]
Medroxyprogesterone acetate for peak identification, European Pharmacopoeia (EP) Reference Standard
Medroxyprogesterone acetate for system suitability, European Pharmacopoeia (EP) Reference Standard
Medroxyprogesterone acetate, 97%
Medroxyprogesterone acetate, European Pharmacopoeia (EP) Reference Standard
Medroxyprogesterone acetate, for performance test, European Pharmacopoeia (EP) Reference Standard
Medroxyprogesterone Acetate, Pharmaceutical Secondary Standard; Certified Reference Material
Medroxyprogesterone acetate, United States Pharmacopeia (USP) Reference Standard
Medroxyprogesterone-17-acetate
Medroxyprogesteroneacetate
Mepastat
Meprate
Methylacetoxyprogesterone
Metigestrona
MLS000069442
MLS001148217
MLS002207115
MolPort-001-794-638
MPA GYM
MPA Hexal
MPA-beta
MPA-Noury
MRF-0000023
Nadigest
NC00574
NCGC00022037-03
NCGC00022037-04
NCGC00022037-05
NCGC00022037-07
NCGC00094713-01
NCGC00257695-01
NCGC00263480-01
Nidaxin
NSC 21171
NSC-21171
NSC-26386
NSC21171
NSC26386
ONCO-Provera
Opera_ID_1110
Oragest
P097000000
Perlutex
Perlutex Leo
Pregn-4-ene-3, 17-(acetyloxy)-6-methyl-, (6.alpha.)-
Pregn-4-ene-3, 17-hydroxy-6.alpha.-methyl-, acetate
Pregn-4-ene-3,20-dione, 17-(acetyloxy)-6-methyl-, (6a)-
Pregn-4-ene-3,20-dione, 17-(acetyloxy)-6-methyl-, (6alpha)-
Pregn-4-ene-3,20-dione, 17-hydroxy-6alpha-methyl-, acetate
Pregn-4-ene-3,20-dione, 17-hydroxy-6alpha-methyl-, acetate (8CI)
PREMPHASE (PREMARIN;CYCRIN 14/14)
PREMPRO (PREMARIN;CYCRIN)
Prodasone
Progestalfa
Progesterone, 17-alpha-hydroxy-6-alpha-methyl-, acetate
Progesterone, 17-hydroxy-6alpha-methyl-, acetate
Progestins
Progevera
Promone-E
Provera
Provera (TN)
Provera dosepak
Proverone
PSGAAPLEWMOORI-PEINSRQWSA-N
PubChem13062
Ralovera
Repromap
Repromix
s2567
SAM002564220
SCHEMBL4276
Sirprogen
SMR000059125
SMR000653524
Sumiferm
Supprestral
Suprestral
Tox21_111319
Tox21_111319_1
Tox21_200141
U 8839
UNII-C2QI4IOI2G
Veramix
Veraplex
ZINC5029557

US Patents and Regulatory Information for DEPO-SUBQ PROVERA 104

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pharmacia And Upjohn DEPO-SUBQ PROVERA 104 medroxyprogesterone acetate INJECTABLE;SUBCUTANEOUS 021583-001 Dec 17, 2004 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Subscribe to access the full database, or Start Trial

Supplementary Protection Certificates for DEPO-SUBQ PROVERA 104

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0113964 97C0037 Belgium   Start Trial PRODUCT NAME: OESTROGENES EQUINS CONJUGUES; ACETATE DE MEDROXYPROGESTERONE; NAT. REGISTRATION NO/DATE: NL 19569 19950301; FIRST REGISTRATION: CH - 52647 01 010 19940826
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Subscribe to access the full database, or Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Johnson and Johnson
Mallinckrodt
Colorcon
Boehringer Ingelheim
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
Copyright 2002-2019 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2019 - 2020
 NCE-1 Patent Challenge Dates 2019 - 2020
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2019, www.DrugPatentWatch.com.

Links

Follow DrugPatentWatch:

DrugPatentWatch reviews